Hereditary Leiomyomatosis And Renal Cell Cancer: Disease Bioinformatics
Hereditary Leimyomatosis and Renal Cell Cancer (HLRCC) is a rare (100 reported cases worldwide) disease where benign tumors containing smooth muscle tissue (leiomyomas) grow in the skin and in the uterus, for females, around the age of 30-40 years old. The tumors will present themselves all over the body and may be painful, but they are not cancerous. This condition increases the risk of kidney cancer (10-16% of individuals with HLRCC develop renal cell cancer), specifically papillary renal cell cancer type 2. In cases where renal cell cancer does not develop, the disorder may be referred to as cutaneous leiomyoatosis (MCL) or multiple cutaneous and uterine leiomyomatosis (MCUL). Hereditary leimyonatosis and renal cell cancer is caused from mutations in the FH gene which controls the creation of the enzyme fumarase, which functions in the Krebs cycle, allowing cells to use oxygen for energy. This disorder is inherited through an autosomal dominant pattern.
Hereditary Leiomyomatosis And Renal Cell Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Hereditary Leiomyomatosis And Renal Cell Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 1958 products for the study of Hereditary Leiomyomatosis And Renal Cell Cancer that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Chromatin Immunoprecipitation (ChIP), Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Hereditary Leiomyomatosis And Renal Cell Cancer is also known as hereditary leiomyomatosis and renal cell cancer, hlrcc, uterine fibroids, leiomyomatosis and renal cell cancer, hereditary, lrcc, hereditary leiomyomatosis and renal cell carcinoma, multiple cutaneous and uterine leiomyomata, leiomyomatosis and renal cell cancer, leiomyoma, multiple cutaneous, multiple cutaneous leiomyoma, reed's syndrome, uterine fibroid, leiomyomatosis, mcul, mcl.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.